United States Patent 12,133,859 Scope Analysis: Topical Gel Claims for Clindamycin Phosphate + Benzoyl Peroxide + Adapalene
US Drug Patent 12,133,859 claims a specific three-active topical gel for acne, defined by (i) tight quantitative ranges for clindamycin phosphate, benzoyl peroxide, and adapalene, (ii) particle-based definitions for both benzoyl peroxide and adapalene, (iii) a gelling system broadly covering many polymer classes with specific embodiments (including carbomer homopolymer Type C and other deprotonatable carboxy-containing crosslinked polymers), and (iv) stability/performance requirements (including room temperature and refrigerated stability windows) plus optional formulation exclusions (no organic solvents beyond polyhydric alcohol, no ionic surfactants, limited preservatives).
The independent claim 1 is broad on gelling agent selection and polyhydric alcohol identity, but narrow on drug loadout and particle-based implementation. Dependent claims add enforceable limitations around exact compositions, specific gelling agents, pH window, particle sizes, dispersion homogeneity, compatibility, and formulation constraints.
What does US patent 12,133,859 claim for clindamycin benzoyl peroxide adapalene topical gel?
Claim 1 is the core scope. It requires a topical gel comprising all of the following:
- Clindamycin phosphate: 1.0 to 1.5 wt. %
- Benzoyl peroxide: 2.5 to 3.5 wt. %
- “plurality of benzoyl peroxide particles”
- Adapalene: 0.15 to 0.20 wt. %
- “plurality of adapalene particles”
- A gelling agent
- An additional agent as a polyhydric alcohol
- Water
Functional perimeter: the claim does not require a specific pH, but dependent claims do. It also does not require a specific manufacturing process, but particle and dispersion language constrains practical formulation architecture.
Claim 1 key infringement-relevant elements
- Three-actives must coexist in one gel: clindamycin phosphate + benzoyl peroxide + adapalene.
- Benzoyl peroxide must be particle-based (not a dissolved molecular form).
- Adapalene must also be particle-based (not only solubilized).
- A “polyhydric alcohol” must be present in addition to the other components.
- A gelling agent is mandatory, but the specific gelling agent can be selected later within dependent claim limits.
How narrow are the quantitative ranges in claim 1 for clindamycin phosphate, benzoyl peroxide, and adapalene?
Claim 1 sets ranges that map to a typical “thin corridor” for formulation design. The independent claim breadth is determined by these ranges.
| Component |
Claim 1 wt. % range |
Practical design implication |
| Clindamycin phosphate |
1.0–1.5 |
Excludes 0.5–0.9 and >1.5 designs |
| Benzoyl peroxide |
2.5–3.5 |
Excludes <2.5 and >3.5 loadings |
| Adapalene |
0.15–0.20 |
Excludes lower adapalene strengths and >0.20 |
Dependent claim 2 further narrows to nominal “about” values:
- Clindamycin phosphate about 1.2 wt. %
- Benzoyl peroxide about 3.1 wt. %
- Adapalene 0.15 wt. %
This combination is a likely target for commercial generic/line-extension designs because it mirrors typical dose-loading for fixed-combination acne gels.
What do the “plurality of particles” limitations do to the claim scope?
Claims 1, 12, 13, and 14 create a particle-centric scope:
- Claim 1: both benzoyl peroxide and adapalene are present as pluralities of particles.
- Claim 12: benzoyl peroxide particles are homogeneously dispersed.
- Claim 13: benzoyl peroxide particle mean size 1 to 50 microns.
- Claim 14: adapalene particles are homogeneously dispersed.
Infringement pressure: product development teams typically evaluate whether their drug forms are suspended (particle-based) versus molecularly dissolved. If a competitor solubilizes adapalene and/or benzoyl peroxide beyond what can be measured as particles within the claimed definition, they may seek non-infringement arguments against the “particles” limitation. Conversely, if particle suspensions are used (common in acne gels), these claims are a close fit.
What formulation features are required by the gelling agent claims in US patent 12,133,859?
Claim 1 requires a gelling agent but leaves selection open. Dependent claims constrain gelling options.
Claim 8: broad polymer class coverage
Claim 8 defines an expansive selection list including (non-exhaustive but representative):
- Cellulose derivatives: hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, hydroxypropylmethylcellulose
- Vinyl polymers: carboxyvinyl polymers; crosslinked variants with allyl ethers of polyalcohols; carboxyvinyl copolymers
- Acrylics: polyacrylates, acrylate copolymers
- Specialty polyacrylamides: acrylamide/sodium acryloyldimethyltaurate copolymers
- Polyvinyl alcohol, polyethylene oxide
- Alginate-type: propylene glycol alginates
- Gums: xanthan gum, carrageenan gum
- Combinations
Claim 9: specific embodiment
- carbomer homopolymer Type C
Claim 10: deprotonatable carboxy-containing crosslinked gelling agent
- gelling agent is a crosslinked polymer comprising carboxy moieties
- formulation includes a base selected from KOH / NaOH
- base amount deprotonates carboxy moieties to cause thickening
This adds a more chemistry-anchored design constraint: thickening via deprotonation of carboxyl groups using KOH/NaOH, rather than relying solely on neutral polymer thickening.
Claim 11 and related embodiments
- gelling agent amount: 1.5 to 2 wt. %
How do pH and specific ingredient amounts expand claim 1 into narrower enforceable subsets?
Claim 3: “about” nominal formulation specifics
- Polyhydric alcohol: propylene glycol ~5 wt. %
- Gelling agent: carbomer homopolymer Type C ~1.75 wt. %
- KOH to achieve pH 5–6
This claim is a tight blueprint-like subset. Products engineered to exactly hit a pH outside 5–6 would aim to avoid this dependent claim, but they could still fall within claim 1 and other dependent claim scopes.
Claims 4–7: stability-based limitations
These claims create additional enforceable constraints that can be tested through stability studies:
- Claim 4: stable at room temperature at least six weeks
- Claim 5: stable at room temperature at least ten weeks
- Claim 6: stable 36–46°F, then stable at or below 77°F for at least six weeks
- Claim 7: stable 36–46°F prior to dispensing, then stable at or below 77°F for at least ten weeks
Scope effect: stability windows can be a meaningful barrier to “design-around by swapping carriers,” because stability failures can avoid dependent claims but do not necessarily avoid independent claim 1 unless stability is also required there.
Which particle and compatibility limitations create the highest design-around pressure?
Particle size and dispersion
- Claim 13: benzoyl peroxide particle mean size 1–50 microns
- Claim 12: homogeneously dispersed benzoyl peroxide particles
- Claim 14: homogeneously dispersed adapalene particles
Compatibility/interaction
- Claim 15: adapalene and benzoyl peroxide do not undergo “any detrimental interaction”
This introduces a performance/compatibility requirement. It is not limited by a measurable chemical marker in the text you provided, but it is enforceable as a claimed property. In litigation, a patentee can frame failure based on observed degradation, loss of potency, or visible/instrumented changes tied to “detrimental interaction.”
What exclusions and ingredient constraints are written into dependent claims?
These are typical levers for formulation teams and generic counterpart developers.
- Claim 17: formulation is free of additional agents as organic solvents other than the polyhydric alcohol
- Claim 19: formulation is free of ionic surfactants
- Claim 20: formulation is free of preservatives other than the polyhydric alcohol
- Claim 16: polyhydric alcohol selection list includes:
- propylene glycol, ethoxydiglycol, polyethylene glycol, glycerol
- Claim 18: polyhydric alcohol amount 3–7 wt. %
These constraints narrow permissible excipient packages. A competitor adding other solvents, ionic surfactants, or preservatives could aim to avoid particular dependent claims, but may still face independent claim 1 if the added components do not eliminate required elements.
What is the likely patent landscape around a clindamycin + benzoyl peroxide + adapalene fixed-combination gel?
Your inputs define only the text of US 12,133,859 claims and not the wider family, assignee, priority dates, related continuations, or citation chain. Under strict analysis rules, a full “landscape” across other patents cannot be completed from claim text alone.
However, the claim architecture itself indicates where the broader estate and litigation focus usually concentrates:
Technical claim clusters likely protected elsewhere in the estate (by inference from claim structure)
- Particle-size-controlled peroxide dispersion (benzoyl peroxide)
- Suspended adapalene compatibility within a peroxide-containing vehicle
- Specific stabilizing excipient system (polyhydric alcohol + polymer gel network)
- pH-thickening using KOH/NaOH with carboxyl-containing gelling polymers
- Stability at refrigerated and warm temperatures
- Compatibility testing to avoid “detrimental interaction”
Design-around vectors suggested by the claim boundaries
- Move outside the drug loading ranges (clindamycin 1.0–1.5, peroxide 2.5–3.5, adapalene 0.15–0.20)
- Use alternate forms that are not “plurality of particles” by the relevant characterization method
- Engineer peroxide particle mean size outside 1–50 microns
- Avoid ionic surfactants and additional organic solvents (already claimed as exclusions in dependent claims, so these are not needed to avoid the core)
- Use alternative gelling systems outside the dependent claim polymer lists (but claim 1 only requires a gelling agent, so avoidance must be complete, not partial)
How strong is the patent scope for generic or licensed entry risk under US Hatch-Waxman?
From the claim text alone, the independent claim is formulation-structure centric. That typically translates into higher enforceability against direct composition-and-structure infringement, because the claim reads on the finished gel.
Why claim 1 is hard to design around quickly
- It requires three actives together at specific wt. % ranges.
- It requires both actives to be present as particles.
- It requires a polyhydric alcohol and a gel matrix.
A generic entrant that matches all three actives and targets similar label strengths risks falling inside claim 1 even if it uses a different polymer, provided it still uses some gelling agent and meets the particle and excipient requirements.
Where dependent claims create additional checkpoints
Dependent claims 2, 3, 8–11, 12–15, 16–20 add narrower enforceable conditions. A generic can sometimes target noninfringement by moving outside a dependent parameter while still potentially risking independent claim 1. The practical litigation question becomes whether those modifications avoid at least one element of claim 1 (not just a dependent claim).
What expiration or Orange Book status applies to US 12,133,859?
No Orange Book listing data, patent-term-expiration, or regulatory exclusivity timeline is provided in your input. Without the underlying FDA NDA/ANDA/BLA mapping for this patent number and without priority/filing dates, no accurate expiration analysis can be produced.
Key Takeaways
- US 12,133,859 claim 1 covers a topical gel containing clindamycin phosphate (1.0–1.5 wt. %), benzoyl peroxide (2.5–3.5 wt. % as dispersed particles), and adapalene (0.15–0.20 wt. % as dispersed particles) in a gelling matrix with a polyhydric alcohol and water.
- Particle-based limitations for both peroxide and adapalene are central. Dependent claims tighten particle homogeneity and benzoyl peroxide mean size (1–50 microns).
- Gelling agent scope is broad at claim 1 level, but dependent claims add enforceable subsets, including carbomer homopolymer Type C and carboxyl-containing deprotonated crosslinked polymers using KOH/NaOH.
- Stability constraints (room temperature and refrigerated to warm windows) create additional measured performance boundaries.
- Compatibility (“no detrimental interaction”) is a functional constraint that can drive evidence and testing in disputes.
- Excipient exclusions/constraints (no organic solvents beyond polyhydric alcohol, no ionic surfactants, no preservatives other than polyhydric alcohol) narrow allowable formulation changes.
FAQs
- Can a product avoid infringement by changing gelling agents under US 12,133,859?
- How do benzoyl peroxide particle size and “homogeneously dispersed” language affect design-around strategies?
- Does moving pH outside 5–6 avoid protection in claim 3?
- What is the legal effect of “no detrimental interaction” between adapalene and benzoyl peroxide in claim 15?
- If a formulation uses propylene glycol vs glycerol for the polyhydric alcohol, which dependent claims change?
References (APA)
- United States Patent 12,133,859 (claims provided in prompt).
